Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Whole genome sequencing unlikely to be funded by government health plans

Tony Morris
CMAJ April 23, 2018 190 (16) E513; DOI: https://doi.org/10.1503/cmaj.69223
Tony Morris
Pathologist, Red Deer Regional Hospital Centre, Red Deer, Alta.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The findings of the Personal Genome Project (PGP) are ambiguous because they tell only part of the story of genetic disease.1 It is common to use the words “genetic” and “inherited” interchangeably; however, there are two major components to genetic disease. The first is inherited genes, exhaustively examined in the PGP using whole genome sequencing, and the second, more important, is acquired (noninherited) genetic somatic mutations. In the dividing cells of the body, DNA replication is imperfect and results in random mutations, which are so common that fetal neurons contain 200–400 somatic mutations per cell by 15–21 weeks postconception.2 No two cells in our body are genetically identical, and the impact and complexity of this mosaicism on the phenotypic expression of disease is underestimated in general3 and unaccounted for in the PGP.

Many of the common diseases that our patients are concerned about are sporadic and noninherited genetic disorders. Cancer is a disease of acquired mutations; sporadic cancer requires at least two somatic mutations in a single cell (clone). Individuals with an inherited familial mutation, (e.g., the BRCA mutation) need an additional somatic mutation to develop cancer. Clonal mutations resulting in proteinopathies (e.g., antibodies and T-cell receptors) can lead to autoimmune disorders such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Neurodegenerative proteinopathies include Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis (ALS). These clonal somatic mutations cannot be detected by whole genome sequencing of blood DNA.

Whole genome sequencing technology is impressive, and, as the cost of testing falls, it may become the technology of choice for specific genetic testing, such as prenatal, familial, pharmacogenetic or cancer tissue genetic studies. Nevertheless the cost of generating an interpretive report, the family physician’s time for consultation and the need for genetic counselling will increase substantially. Owing to its limitations to only the inherited genome and lack of specificity (false positives), whole genome sequencing is unlikely to be useful or interpretable as a laboratory screening test, let alone be funded by provincial health systems as a routine test.

Footnotes

  • Competing interests: None declared.

References

  1. ↵
    1. Reuter MS,
    2. Walker S,
    3. Thiruvahindrapuram B,
    4. et al
    . The Personal Genome Project Canada: findings from whole genome sequences of the inaugural 56 participants. CMAJ 2018;190:E126–36.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Bae T,
    2. Tomasini L,
    3. Mariani J,
    4. et al
    . Different mutational rates and mechanisms in human cells at pregastrulation and neurogenesis. Science 2018; 359:550–5.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Campbell IM,
    2. Shaw CA,
    3. Stankiewicz P,
    4. et al
    . Somatic mosaicism: implications for disease and transmission genetics. Trends Genet 2015;31: 382–92.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 190 (16)
CMAJ
Vol. 190, Issue 16
23 Apr 2018
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Whole genome sequencing unlikely to be funded by government health plans
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Whole genome sequencing unlikely to be funded by government health plans
Tony Morris
CMAJ Apr 2018, 190 (16) E513; DOI: 10.1503/cmaj.69223

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Whole genome sequencing unlikely to be funded by government health plans
Tony Morris
CMAJ Apr 2018, 190 (16) E513; DOI: 10.1503/cmaj.69223
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • The Personal Genome Project Canada: findings from whole genome sequences of the inaugural 56 participants
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire